A5001341362- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- Cancer Immunotherapy and Biomarkers
- Cell Adhesion Molecules Research
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Epigenetics and DNA Methylation
- Advanced Drug Delivery Systems
- Atrial Fibrillation Management and Outcomes
- Nanoparticle-Based Drug Delivery
- Cancer Research and Treatments
- Bioactive natural compounds
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Melanoma and MAPK Pathways
- Lung Cancer Treatments and Mutations
- Glycosylation and Glycoproteins Research
- Cancer Treatment and Pharmacology
- Cardiac tumors and thrombi
- CNS Lymphoma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Calcium signaling and nucleotide metabolism
- Lymphoma Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Liver Disease Diagnosis and Treatment
First Affiliated Hospital of Dalian Medical University
2022-2025
Dalian Medical University
2022-2025
Abstract Amivantamab is the first dual-specificity antibody targeting EGFR and MET, which approved for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon 20 insertion mutations. Cardiovascular toxicities related to amivantamab have not been reported in CHRYSALIS study. However, occurrence cardiovascular events real world unknown. To comprehensively investigate clinical characteristics, onset times, outcomes associated amivantamab. The Food Drug...
Glycan-based scaffolds are unique in their high specificity, versatility, low immunogenicity, and ability to mimic natural carbohydrates, making them attractive candidates for use cancer treatment. These made up of glycans, which biopolymers with well biocompatibility the human body that can be used drug delivery. The versatility glycan-based allows modulation activity targeted delivery specific cells or tissues, increases potency drugs reduces side effects. Despite promise, there still...
ABSTRACT Background Metabolic reprogramming, an essential hallmark of pancreatic cancer (PC), affects the treatment and prognosis patients with this malignancy. For nonresectable PC, chemotherapy is primary option, gemcitabine recognized as a first‐line chemotherapeutic drug. However, effectiveness often compromised by rapid development drug resistance. This study investigated metabolic targets in PC under evaluated potential matrine, Chinese herb extract, adjuvant therapy for PC. Methods We...
Abstract Immune checkpoint inhibitors (ICIs) have significantly improved the efficacy and prognosis of patients with non-small cell lung cancer (NSCLC). However, there remains a lack optimal predictive biomarkers for assessing response ICIs. This study aimed to evaluate peripheral inflammatory factors as potential NSCLC treated We retrospectively analyzed correlation between 124 driver gene-negative advanced who received first-line ICIs at our center from September 2018 June 2022....
EGFR and HER2 dual TKIs have been approved for the treatment of advanced breast cancer in patients who are HER2-positive second and/or third-line treatment. However, there is a lack attention to cardiovascular adverse events (AEs) caused by TKIs. We analyzed data spanning between March 2007 June 2024 using FAERS database reporting odds ratio, proportional Bayesian confidence propagation neural network perform disproportionality analysis. Compared with non-cardiovascular AEs, AEs were...
e24013 Background: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in cancer patients. However, current predictive tools, such as the Caprini risk assessment model (Caprini RAM), have limitations. This research aimed to evaluate value Controlling Nutritional Status (CONUT) score for VTE high-risk hospitalized patients based on CRA model, create novel forecasting Methods: single-center, retrospective study included 2081 identified using RAM, treated between January...
4174 Background: Immune checkpoint inhibitors targeting PD-1 and CTLA-4 have shown success in various cancers; however, their efficacy pancreatic cancer remains limited, likely due to its immunosuppressive microenvironment. Treg cells are crucial tumor immune evasion suppression. Targeting is an emerging strategy immunotherapy. Recent studies show that USP22 (Ubiquitin-Specific Protease 22) regulates immunity by deubiquitinating key proteins like PD-L1 STAT1 cells, while controls FoxP3,...
e20033 Background: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, highly aggressive malignancy with poor prognosis, accounting for approximately 3% of all lung cancers. LCNEC exhibits features both small-cell cancer (SCLC) and non-small-cell (NSCLC), complicating diagnosis treatment strategies. This study aims to identify clinical characteristics prognostic factors in patients following surgery resection. Methods: retrospective evaluated 44 histologically confirmed who...
Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer, and the therapy options for PDAC remain restricted. The distinctive tumor immunological microenvironment (TIME) of PDAC, comprising high number stromal cells limited infiltration cytotoxic T lymphocytes (CTLs), rendered immunotherapy ineffective. protein level ubiquitin-specific protease 43 (USP43) was prognostic predictor in numerous cancers; however, its function limited. This article focuses on influence USP43 expression...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor prognosis. Reprogramming of amino acid metabolism one the characteristics PDAC, in which arginine significantly altered PDAC cells and involved important signaling pathways. Current studies have identified deprivation as potential strategy for treatment. In this study, we performed Liquid Chromatograph Mass Spectrometer (LC-MS)-based non-targeted metabolomic analysis on cell lines stable Rio Kinase 3 (RIOK3)...
Pancreatic cancer (PC) is burdened with a low 5-year survival rate and high mortality due to severe lack of early diagnosis methods slow progress in treatment options. To improve clinical enhance the effects, we applied metabolomics using ultra-high-performance liquid chromatography high-resolution mass spectrometer (UHPLC-HRMS) identify validate metabolite biomarkers from paired tissue samples PC patients. Results showed that metabolic reprogramming mainly featured enhanced amino acid...
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer, characterized by a high metastatic burden. RIO Kinase 3 (RIOK3) has been shown to promote invasion and metastasis of PDAC cytoskeleton remodeling, but the exact mechanism still unknown. In this study, we analyzed transcriptome sequencing data from RIOK3 stable knockdown PANC-1 cells TCGA-PDAC discovered that was substantially related focal adhesion signaling in PDAC. Additionally, silencing dramatically decreased...
The purpose of this study is to determine the efficacy and safety lenvatinib as second-line therapy in Chinese patients with unresectable hepatocellular carcinoma (HCC). We performed a retrospective analysis HCC who received treatment at three institutions from November 2018 February 2022. Demographic clinicopathologic characteristics, data on regimens were obtained medical records. Tumor response was evaluated every 4-6 weeks by modified Response Evaluation Criteria Solid Tumors (mRECIST)....
Cancer diagnoses and deaths among the elderly (65 +) are expected to increase significantly over next decade. Immune checkpoint inhibitors specifically target ICI genes enhance immune system function. However, poor outcomes may be associated with aging.We downloaded Genomic Data Commons from Genome Atlas (TCGA) collected gene expression data malignant melanoma (MM) tissues, third level as primary site. The CKTTD database were applied validated using GEO lab experiments.In 414 patients, 13...
<title>Abstract</title> Background The aberrant activation of FAK (Focal Adhesion Kinase) serves as a critical mechanism leading to heightened invasiveness and metastatic potential in pancreatic ductal adenocarcinoma (PDAC). inhibitors have entered clinical trials, underscoring the significance targeting treating PDAC. Further exploration regulation is crucial for advancing inhibitors. Our previous study suggests that RIO Kinase 3 (RIOK3) facilitates metastasis PDAC cells by stabilizing...
Background Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin and may occur with lymph node and/or extranodal involvement. However, DLBCL intracardiac mass exceedingly rare. In reported literature, infiltration mostly involves right ventricle. Lymphoma that invades heart has an aggressive nature, symptoms are easily ignored initially can lead to multiple complications in severe cases, resulting a poor prognosis. Early screening diagnosis significantly improve...